Drug Trial Radar · NCT05299073
A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
257
Actual
Start
Mar 1, 2022
Primary completion
Mar 18, 2023
Study completion Mar 18, 2023
Sponsor
- Lead sponsor
- mAbxience Research S.L.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 28 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, PD, safety and immunogenicity profile of MB09 with EU/US-Xgeva® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Pharmacodynamics, safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.
Conditions
- Healthy Volunteers
Interventions
MB09Drug
Single dose of 35mg SC administered
US-sourced XgevaDrug
Single dose of 35mg SC administered
EU-sourced XgevaDrug
Single dose of 35mg SC administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-lastTime frame: Day 1 to Day 253
- CmaxTime frame: Day 1 to Day 253
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Biokinetica - Early Phase Institute
Józefów, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.